Atossa Therapeutics executes contingent value rights agreement for potential priority review voucher value
ATOS•Atossa Therapeutics declared one stapled contingent value right per share as of October 19, 2026. Holders will be entitled to 25% of net proceeds, subject to a $50 million aggregate cap.
1. CVR terms
Atossa Therapeutics executed a contingent value rights agreement providing shareholders participation in potential priority review voucher value. The company declared one stapled CVR per share as of October 19, 2026; CVR holders are entitled to 25% of net proceeds, with a $50 million aggregate cap.
